

NOV 07 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


OFFICIAL

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Examiner: Yaen, Christopher H.
Group Art Unit: 1642
Title: Allogeneic Cellular Immunogens Useful as
Cancer Vaccines

Certificate of Facsimile Transmission

I hereby certify that this document is being facsimile
transmitted to the Patent and Trademark Office on
the date shown below.

On November 7, 2003


Kathleen A. Tyrrell, Registration No. 38,350

Mail Stop
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Reply under 37 C.F.R. §1.111

This is a reply to the Office Action mailed September 23,
2003 setting a three (3) month statutory period for response.

Please enter the following remarks and amendments into the
record.

Amendments to the claims are reflected in the listing of
claims which begins on page 3 of this paper.

Attorney Docket No.: MCP-0141
Inventors: Halpern and England
Serial No.: 09/744,406
Filing Date: January 22, 2001
Page 2

Remarks begin on page 8.

FACSIMILE COVER SHEET

RECEIVED
CENTRAL FAX CENTER

NOV 07 2003

Licata & Tyrrell P.C.66 E. Main Street
Marlton, New Jersey**OFFICIAL**Tel: (856) 810-1515
Fax: (856) 810-1454

November 7, 2003


TO: Examiner Yaen (TC1600)**GROUP: 1642****FAX NUMBER: 703-872-9307****ATTORNEY DOCKET NO.: MCP-0141****SERIAL NO.: 09/744,406****FILED: January 22, 2001****NUMBER OF PAGES:****MESSAGE:** Attached please find Amendment Transmittal Letter (in duplicate); Reply under 37 CFR 1.111 mailed September 23, 2003; and Certificate of Transmission by Facsimile.**Kathleen A. Tyrrell, Registration No. 38,350****URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!**


* * * * *

If you have any questions, or did not receive the proper number of pages, or had trouble during transmission, please call 856-810-1515.

CONFIDENTIALITY NOTICE

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney-client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No. 7933-38 (MCP-0141)
Applicant(s): Halpern and England			
Serial No. 09/744,406	Filing Date January 22, 2001	Examiner Yaen, Christopher H.	Group Art Unit 1642
Invention: Allogeneic Cellular Immunogens Useful as Cancer Vaccines			
<p>I hereby certify that this <u>Reply under 37 CFR 1.111</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9307</u>) on <u>November 7, 2003</u> (Date)</p> <p style="text-align: center;"><u>Kathleen A. Tyrrell</u> (Typed or Printed Name of Person Signing Certificate)  (Signature)</p>			
<p>Note: Each paper must have its own certificate of mailing.</p>			

AMENDMENT TRANSMITTAL LETTER (Small Entity)		Docket No. MCP-0141				
Applicant(s): Halpern and England						
Serial No. 09/744,406	Filing Date January 22, 2001	Examiner Yaen, Christopher H.	Group Art Unit 1642			
Invention: Allogeneic Cellular Immunogens Useful as Cancer Vaccines						
<u>TO THE COMMISSIONER FOR PATENTS:</u>						
Transmitted herewith is an amendment in the above-identified application.						
<input type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted. <input type="checkbox"/> A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
TOTAL CLAIMS	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
13	20 =	0 x	\$9.00	\$0.00		
INDEP. CLAIMS	2	3 =	0 x	\$43.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00		
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT				\$0.00		
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____. <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-1619 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.						
 <u>Kathleen A. Tyrrell</u> <small>Signature</small> Kathleen A. Tyrrell, Reg. No. 38,350						
Dated: November 7, 2003						
<div style="border: 1px solid black; padding: 5px;"> I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. </div>						
<div style="border: 1px solid black; padding: 5px;"> <small>Signature of Person Mailing Correspondence</small> </div>						
<div style="border: 1px solid black; padding: 5px;"> <small>Typed or Printed Name of Person Mailing Correspondence</small> </div>						
CC:						